ArticleNature2024
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques.
Open access · hybridAbstract readComparative Study
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
16.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial.Nature communications · 2025Trial
- A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV-Important Lessons Learned.Journal of medical primatology · 2026Article
- Spatiotemporal heterologous vaccination relies on type I interferons at priming to enhance mucosal immunity.EMBO molecular medicine · 2026Article
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Intranasal Adenoviral Vector Vaccination Induces Durable Antibody and T Cell Responses in the Respiratory Tract.Vaccines · 2026Article
- A novel cystic fibrosis-mimetic Pseudomonas auxotrophic vaccine is protective in vivo and is associated with IL-17/IgA mucosal Immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- From injection to inhalation: A STING-activating mucosal adjuvant reprograms vaccination.Clinical and translational medicine · 2026Article
- Article
- Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid.PLoS pathogens · 2026Article
- Harnessing mucosal immunity for protective vaccines.Nature reviews. Immunology · 2026Review
- Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice.Nature communications · 2026Article
- Early innate immune signatures correlate with Ad26.COV2.S vaccine durability and protective efficacy.bioRxiv : the preprint server for biology · 2026Article
- Combating respiratory diseases with mucosal vaccines.Journal of virology · 2026Review
- A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Mucosal Vaccine Development: From Adjuvant Design to Next-Generation Delivery Strategies.Biomedicines · 2026Review
- Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.iScience · 2026Article
- The B cell receptor-mTOR signaling axis restricts the accumulation of lung tissue-resident memory B cells after influenza infection.Science immunology · 2026Article
- Engineered mucus-tethering bispecific nanobodies enhance mucosal immunity against respiratory pathogens.Nature nanotechnology · 2026Article
- Intranasal booster drives class switching and homing of memory B cells for mucosal IgA response.JCI insight · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 6 institutions in 2 countries.
Katherine McMahan *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Frank Wegmann *Janssen Vaccines and Prevention, Leiden, Netherlands.ORCID 0000-0002-9821-1492
Malika Aid *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Michaela Sciacca *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jinyan Liu *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Nicole P Hachmann *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0002-2100-8461
Jessica Miller *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Catherine Jacob-Dolan *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0001-6641-0342
Olivia Powers *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
David Hope *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0001-5654-1744
Cindy WuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0001-6924-5346
Juliana PereiraCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0009-0004-0505-6051
Tetyana MurdzaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0003-1800-1784
Camille R MazurekCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0002-0899-2548
Amelia HoytCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0003-1307-2508
Adrianus C M BoonWashington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-4700-8224
Meredith Davis-GardnerEmory School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-6133-3613
Mehul S SutharEmory School of Medicine, Atlanta, GA, USA.
Amanda J MartinotTufts University Cummings School of Veterinary Medicine, Grafton, MA, USA.ORCID 0000-0001-6237-6191
Mona BoursiquotBioqual, Rockville, MD, USA.
Anthony CookBioqual, Rockville, MD, USA.
Laurent PessaintBioqual, Rockville, MD, USA.
Mark G LewisBioqual, Rockville, MD, USA.ORCID 0000-0001-7852-0135
Hanne AndersenBioqual, Rockville, MD, USA.ORCID 0000-0003-1103-9608
Jeroen TolboomJanssen Vaccines and Prevention, Leiden, Netherlands.
Jan SerroyenJanssen Vaccines and Prevention, Leiden, Netherlands.
Laura SolforosiJanssen Vaccines and Prevention, Leiden, Netherlands.ORCID 0000-0003-3786-6468
Lea M M CostesJanssen Vaccines and Prevention, Leiden, Netherlands.
Roland C Zahn *Janssen Vaccines and Prevention, Leiden, Netherlands.ORCID 0000-0003-2822-6231
Dan H Barouch *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA. dbarouch@bidmc.harvard.edu.ORCID 0000-0001-5127-4659
Beth Israel Deaconess Medical Center · USJanssen (Netherlands) · NLBioqual · USEmory University · USTufts University · USWashington University in St. Louis · US
Funding
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7MNCI NIH HHS U01 CA260476
Abstract
A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against infection with current Omicron subvariants
Indexed as
COVID-19COVID-19 VaccinesImmunity, MucosalImmunization, SecondaryMacaca mulattaSARS-CoV-2Administration, IntranasalAnimalsAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesHumansImmunoglobulin AImmunoglobulin GAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCytokinesImmunoglobulin AImmunoglobulin GmRNA Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.